Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Life Sciences	$1.31 -0.4%	$1.71	$1.03 ▼ $2.64	$259.78M	1.18	1.49 million shs	1.55 million shs
ATYR Atyr PHARMA	$2.62 -6.1%	$3.57	$1.42 ▼ $4.66	$232.81M	0.95	873,693 shs	1.87 million shs
CADL Candel Therapeutics	$4.82 -8.2%	$8.05	$3.79 ▼ $14.60	$227.67M	-1.29	2.15 million shs	1.22 million shs
IFRX InflaRx	$1.01 -3.8%	$1.66	$0.97 ▼ $2.82	$67.80M	2.21	222,897 shs	319,785 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Life Sciences	-0.38%	-10.88%	-18.63%	-25.99%	-45.19%
ATYR Atyr PHARMA	-6.09%	-16.29%	-16.83%	-34.17%	+261,999,900.00%
CADL Candel Therapeutics	-8.19%	-18.99%	-40.79%	-47.72%	+186.90%
IFRX InflaRx	-3.81%	-12.17%	-19.20%	-58.09%	-34.84%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI Atai Life Sciences	3.4164 of 5 stars	3.5	4.0	2.4	3.3	1.3
ATYR Atyr PHARMA	2.5103 of 5 stars	3.6	1.0	3.0	3.3	0.6
CADL Candel Therapeutics	2.1411 of 5 stars	3.5	2.0	1.8	2.5	0.6
IFRX InflaRx	2.4783 of 5 stars	3.5	3.0	2.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI Atai Life Sciences	3.00	Buy	$10.50	701.53% Upside
ATYR Atyr PHARMA	3.14	Buy	$18.60	609.92% Upside
CADL Candel Therapeutics	3.00	Buy	$21.00	335.68% Upside
IFRX InflaRx	3.00	Buy	$9.00	791.09% Upside

Current Analyst Ratings Breakdown

Latest IFRX, ATAI, ATYR, and CADL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/26/2025	IFRX InflaRx	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $10.00
3/21/2025	IFRX InflaRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
3/19/2025	ATAI Atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/14/2025	ATYR Atyr PHARMA	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00
3/14/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
3/7/2025	IFRX InflaRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
2/26/2025	CADL Candel Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $25.00
2/26/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
2/20/2025	CADL Candel Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
2/19/2025	CADL Candel Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
2/18/2025	ATYR Atyr PHARMA	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 4/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI Atai Life Sciences	$308K	843.44	N/A	N/A	$1.47 per share	0.89
ATYR Atyr PHARMA	$235K	990.68	N/A	N/A	$1.54 per share	1.70
CADL Candel Therapeutics	$120K	1,897.27	N/A	N/A	$0.44 per share	10.95
IFRX InflaRx	$165.79K	408.98	N/A	N/A	$1.89 per share	0.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI Atai Life Sciences	-$40.22M	-$0.93	N/A	N/A	N/A	N/A	-65.75%	-52.71%	5/13/2025 (Estimated)
ATYR Atyr PHARMA	-$50.39M	-$0.87	N/A	N/A	N/A	N/A	-79.44%	-59.16%	5/1/2025 (Estimated)
CADL Candel Therapeutics	-$37.94M	-$1.75	N/A	N/A	N/A	N/A	-629.29%	-173.39%	5/13/2025 (Estimated)
IFRX InflaRx	-$46.18M	-$0.87	N/A	N/A	N/A	-33,362.70%	-65.98%	-56.86%	5/6/2025 (Estimated)

Latest IFRX, ATAI, ATYR, and CADL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	N/A	ATYR Atyr PHARMA	-$0.19	N/A	N/A	N/A	N/A	N/A
3/20/2025	Q4 2024	IFRX InflaRx	-$0.27	-$0.09	+$0.18	-$0.09	$0.13 million	N/A
3/17/2025	Q4 2024	ATAI Atai Life Sciences	-$0.14	-$0.24	-$0.10	-$0.24	$0.30 million	($0.01) million
3/13/2025	Q4 2024	ATYR Atyr PHARMA	-$0.23	-$0.18	+$0.05	-$0.18	$0.02 million	N/A
3/13/2025	Q4 2024	CADL Candel Therapeutics	-$0.23	-$0.40	-$0.17	-$0.40	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI Atai Life Sciences	N/A	N/A	N/A	N/A	N/A
ATYR Atyr PHARMA	N/A	N/A	N/A	N/A	N/A
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI Atai Life Sciences	0.14	5.81	5.81
ATYR Atyr PHARMA	0.02	5.41	5.41
CADL Candel Therapeutics	N/A	1.18	1.18
IFRX InflaRx	N/A	5.31	4.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI Atai Life Sciences	28.41%
ATYR Atyr PHARMA	61.72%
CADL Candel Therapeutics	13.93%
IFRX InflaRx	42.39%

Insider Ownership

Company	Insider Ownership
ATAI Atai Life Sciences	31.20%
ATYR Atyr PHARMA	3.70%
CADL Candel Therapeutics	41.60%
IFRX InflaRx	16.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI Atai Life Sciences	80	198.31 million	115.45 million	Optionable
ATYR Atyr PHARMA	53	88.86 million	80.84 million	Optionable
CADL Candel Therapeutics	60	47.24 million	18.97 million	Optionable
IFRX InflaRx	60	67.13 million	56.19 million	Optionable

IFRX, ATAI, ATYR, and CADL Headlines

Recent News About These Companies

InflaRx N.V. Announces 2025 Annual General Meeting Agenda

April 3 at 8:19 AM | tipranks.com

Raymond James Financial Inc. Purchases Shares of 638,092 InflaRx (NASDAQ:IFRX)

April 3 at 3:06 AM | marketbeat.com

Is InflaRx (IFRX) the Best German Stock to Buy According to Hedge Funds?

April 2 at 10:46 PM | msn.com

InflaRx (NASDAQ:IFRX) Given New $10.00 Price Target at Guggenheim

March 28, 2025 | americanbankingnews.com

InflaRx price target raised to $10 from $7 at Guggenheim

March 27, 2025 | markets.businessinsider.com

Guggenheim Raises InflaRx (NASDAQ:IFRX) Price Target to $10.00

March 27, 2025 | marketbeat.com

InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

March 26, 2025 | zacks.com

LifeSci Capital Remains a Hold on InflaRx (IFRX)

March 22, 2025 | markets.businessinsider.com

HC Wainwright Reiterates "Buy" Rating for InflaRx (NASDAQ:IFRX)

March 22, 2025 | marketbeat.com

InflaRx N.V. Receives European Commission Approval for GOHIBIC® (vilobelimab) and Achieves Key Development Milestones in Clinical Trials

March 22, 2025 | nasdaq.com

InflaRx reports Q EPS (EUR 0.78) vs (EUR 0.78) last year

March 21, 2025 | markets.businessinsider.com

InflaRx (NASDAQ:IFRX) Posts Quarterly Earnings Results

March 21, 2025 | marketbeat.com

Promising Prospects for InflaRx’s Gohibic: Buy Rating Supported by Positive Phase 3 Developments and Market Potential

March 21, 2025 | tipranks.com

InflaRx N.V. Reports 2024 Results and Key Achievements

March 21, 2025 | tipranks.com

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

March 20, 2025 | markets.businessinsider.com

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

March 20, 2025 | globenewswire.com

Short Interest in InflaRx (NASDAQ:IFRX) Grows By 46.2%

March 16, 2025 | marketbeat.com

InflaRx (IFRX) Projected to Post Earnings on Thursday

March 13, 2025 | marketbeat.com

HC Wainwright Reiterates Buy Rating for InflaRx (NASDAQ:IFRX)

March 8, 2025 | marketbeat.com

InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

March 7, 2025 | finance.yahoo.com

InflaRx announces presentation of multiple posters on utility of vilobelimab

March 7, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX, ATAI, ATYR, and CADL Company Descriptions

Atai Life Sciences NASDAQ:ATAI

$1.31 -0.01 (-0.38%)

Closing price 04/4/2025 04:00 PM Eastern

Extended Trading

$1.31 0.00 (0.00%)

As of 04/4/2025 07:32 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Atyr PHARMA NASDAQ:ATYR

$2.62 -0.17 (-6.09%)

Closing price 04/4/2025 04:00 PM Eastern

Extended Trading

$2.60 -0.02 (-0.95%)

As of 04/4/2025 07:36 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Candel Therapeutics NASDAQ:CADL

$4.82 -0.43 (-8.19%)

Closing price 04/4/2025 04:00 PM Eastern

Extended Trading

$4.82 0.00 (-0.08%)

As of 04/4/2025 07:38 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

InflaRx NASDAQ:IFRX

$1.01 -0.04 (-3.81%)

Closing price 04/4/2025 04:00 PM Eastern

Extended Trading

$1.01 0.00 (-0.30%)

As of 04/4/2025 05:31 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time